Fiona Gia's questions to Viking Therapeutics Inc (VKTX) leadership • Q4 2024
Question
Fiona Gia asked for more characterization of the amylin agonist candidate that Viking has selected to move forward, specifically regarding its activity profile.
Answer
CEO Brian Lian responded that the compounds of greatest interest have a more balanced profile, with activity close to a 1:1 ratio when comparing calcitonin to amylin 3 receptor activity.